RxDoctor Payments Data

McHaley Hoffman

Family · Hagerstown, MDNPI 1700413515

Payments from drug & device makers

$2,054in general payments, 2019–2025

Across 113 payments — averaging $18.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$494
  • Novo Nordisk$305
  • AstraZeneca$193
  • Lilly USA, LLC$185
  • Amgen$162
  • GSK$139
  • plus $576 from 14 others

What the payments were for

  • Food & beverage$2,054100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,054 in reported general payments places this provider in the 80th percentile of 2,843 family providers in Maryland.

See all family providers in Maryland

Medicare billing

Part B allowed, 2024
$554
Medicare patients
13
Services billed
18

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide49$73,708
MounjaroTirzepatide46$70,618
JulucaDolutegravir/Rilpivirine20$62,833
BiktarvyBictegrav/Emtricit/Tenofov Ala16$59,839
OzempicSemaglutide36$43,795
JardianceEmpagliflozin27$30,192
EliquisApixaban35$29,233
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$22,086
FarxigaDapagliflozin Propanediol16$18,171
TradjentaLinagliptin11$16,761
RybelsusSemaglutide12$13,925
Repatha SureclickEvolocumab16$8,943
Breo ElliptaFluticasone/Vilanterol11$6,745
SymbicortBudesonide/Formoterol Fumarate15$4,490
Albuterol Sulfate HfaAlbuterol Sulfate71$2,659

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$185$144,32695 claims
Viiv Healthcare CompanyJuluca$69$62,83320 claims
GileadBiktarvy$16$59,83916 claims
Novo NordiskOzempic, Rybelsus$305$57,72148 claims
PfizerEliquis$117$29,23335 claims
GSKTrelegy Ellipta, Breo Ellipta$139$28,83132 claims
AstraZenecaFarxiga, Symbicort$193$22,66131 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,843 family providers in Maryland.

Other family in Hagerstown

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →